Yahoo! Finance: Biotechnology Industry News: ARIAD Announces Long-Term Durability-of-Response Data on Ponatinib from Ongoing Phase 1 Study

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

ARIAD Announces Long-Term Durability-of-Response Data on Ponatinib from Ongoing Phase 1 Study Jun 2nd 2013, 13:00 [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced long-term durability-of-response data from its Phase 1 trial of Iclusig® in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia .

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions